[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults

On-screen parenting duo stars in new, original video highlighting relatable parenting moments, educating viewers about meningococcal disease, also known as meningitis GSK’s Ask2BSure...

GSK.LN : 1,854.500 (+0.62%)
GSK : 50.41 (-0.18%)
The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

AZN : 182.85 (+0.18%)
ABBV : 201.55 (-0.57%)
GSK : 50.41 (-0.18%)
3 Bargain-Cheap Small Caps Worth a Second Look

Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally

WEN : 7.30 (+5.04%)
INVA : 22.89 (+0.39%)
GSK : 50.41 (-0.18%)
NBR : 97.40 (+0.91%)
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection 1 *

GSK.LN : 1,854.500 (+0.62%)
GSK : 50.41 (-0.18%)
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract

Bora manufactures more than 20 commercial products for GSK at its Mississauga facility, supporting infectious disease, mental health, dermatology, & other critical therapeutic areas

BORAY : 2.8100 (-3.10%)
GSK.LN : 1,854.500 (+0.62%)
GSK : 50.41 (-0.18%)
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows

Reduction observed in RSV-related hospitalizations in adults aged ≥60 years 1 An observed reduction in major adverse cardiovascular events* in adults...

GSK.LN : 1,854.500 (+0.62%)
GSK : 50.41 (-0.18%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 58.02 (+0.07%)
GSK : 50.41 (-0.18%)
RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of RAPT Therapeutics ...

RAPT : 58.02 (+0.07%)
GSK : 50.41 (-0.18%)
GSK Awards $2M in COiMMUNITY Initiative Grants to Help Close Vaccination Gaps, Commits $3M for 2026

Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...

GSK.LN : 1,854.500 (+0.62%)
GSK : 50.41 (-0.18%)

Barchart Exclusives

Palantir Stock Has a ‘High-Class Problem’: Demand for Its Software Is Far Outpacing Supply
Palantir’s greatest challenge may no longer be demand, but how quickly it can deliver AI software to customers. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.